BioPharmSignal logoBioPharmSignal

Biotech News

argenx to Report Third Quarter 2026 Financial Results and Business Update on October 22, 2026

Argenx (ARGX)ArgenxEarnings

October 15, 2026

Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology innovation company, today announced that it will host a conference call and audio webcast on Thursday, October 22, 2026 at 2:30 PM CET (8:30 AM ET) to discuss its third quarter 2026 financial results and provide a business update.

Related news

REGNRegeneron Pharmaceuticals2026-09-24 20:05 EST

Regeneron to Report Third Quarter 2026 Financial and Operating Results and Host Conference Call and Webcast on October 30, 2026

REPLReplimune Group2026-10-22 12:00 EST

Replimune to Report the Fiscal Second Quarter 2027 Financial Results and Provide Corporate Update on October 28, 2026

BNTXBioNTech2026-10-20 10:45 EST

BioNTech to Report Third Quarter 2026 Financial Results and Corporate Update on November 3, 2026

EXELExelixis2026-10-15 20:05 EST

Exelixis to Release Third Quarter 2026 Financial Results on Thursday, October 29, 2026

RVMDRevolution Medicines2026-10-21 20:05 EST

Revolution Medicines to Report Financial Results for Third Quarter 2026 After Market Close on November 4, 2026

IMVTImmunovant2026-10-21 11:00 EST

Immunovant to Report Financial Results for the Second Fiscal Quarter Ended September 30, 2026, and Provide Business Update on Monday, November 9, 2026

NRIXNurix Therapeutics2026-10-12 20:05 EST

Nurix Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update

GERNGeron2026-10-21 12:00 EST

Geron Plans to Announce Third Quarter 2026 Financial Results on November 4, 2026

TEVATeva Pharmaceutical Industries2026-09-23 20:45 EST

Teva to Host Conference Call to Discuss Third Quarter 2026 Financial Results on November 3, 2026 at 8 a.m. ET

MMSIMerit Medical2026-10-06 20:30 EST

Merit Medical Systems to Announce Third Quarter 2026 Results on October 29, 2026

View all latest news

Argenx

Global Immunology Company Argenx develops therapies for severe autoimmune diseases. Its core commercial asset, VYVGART/efgartigimod, targets FcRn to reduce circulating IgG autoantibodies and has established a commercial base in generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, and selected regional...

Recent company news

ARGXArgenx2026-10-15 05:00 EST

argenx to Report Third Quarter 2026 Financial Results and Business Update on October 22, 2026

ARGXArgenx2026-10-08 05:00 EST

argenx Announces Positive Topline Results from Phase 2 Study of FB102 in Celiac Disease

ARGXArgenx2026-10-08 05:00 EST

argenx Provides Update on Phase 3 UNITY Study of Efgartigimod SC in Sjögren's Disease

ARGXArgenx2026-09-29 12:00 EST

argenx Presents New Data at AANEM and MGFA Scientific Session Showcasing Earlier and Sustained Treatment in MG and CIDP with VYVGART and Progress Across its Neuromuscular Pipeline

ARGXArgenx2026-09-17 20:03 EST

argenx announces results of Extraordinary General Meeting of Shareholders and appointment of Thomas M. Brakel and Khurem Farooq as Non-Executive Directors

Stock data

Close
890.05 USD
Market cap
49.89B USD
Exchange
NASDAQ
Sector
Antibody Drugs
Location
United States